<DOC>
	<DOCNO>NCT01590225</DOCNO>
	<brief_summary>This three-part ( Part A , Part B , Part C ) , open-label , multicenter study boceprevir pediatric participant chronic hepatitis C ( CHC ) genotype 1 ( GT1 ) . In Part A Part B , efficacy safety evaluate participant CHC GT1 non-cirrhotic , treatment naïves ( Part A ) non-cirrhotic , treatment failure ( peg ) interferon/ribavirin cirrhotics ( whether treatment naïve treatment failure ) ( Part B ) . Part C long-term follow study treatment administer period , participant achieve viral clearance allow receive treatment CHC .</brief_summary>
	<brief_title>Efficacy Safety Boceprevir Combination With Peginterferon Alfa-2b Plus Ribavirin Pediatric Subjects With Chronic Hepatitis C Genotype 1 ( P08034 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>CHC GT1 infection least 6 month HCVRNA ≥10,000 IU/mL . Treatment naive , noncirrhotic participant eligible inclusion Study Part A Noncirrhotic subject fail previous ( peg ) interferon/ribavirin treatment CHC cirrhotics , whether treatment naive treatment failure , eligible inclusion Study Part B To participate Study Part C , participant must complete required posttreatment followup Study Part A Part B Weight ≥ 10 kg ≤ 125 kg Body surface area ( BSA ) ≥0.46 m^2 ≤2.5 m^2 Previous liver biopsy histology consistent chronic hepatitis C etiology within 2 year screen visit Participants bridge fibrosis cirrhosis must ultrasound within 6 month screen visit screen visit Day 1 finding suspicious hepatocellular carcinoma Participant must able adhere dose visit schedule Known coinfection human immunodeficiency virus ( HIV ) hepatitis B virus ( HBsAg positive ) For Study Part A , participant receive prior hepatitis C treatment , include herbal remedy , know hepatotoxicity For Study Part B , participant receive treatment ribavirin within 90 day interferon alpha within 30 day prior screen For Study Part B , participant receive previous treatment hepatitis C virus protease inhibitor ( except participant study P07614 , Pharmacokinetics Boceprevir Pediatric Subjects With Chronic Hepatitis C Genotype 1 ) For Study Part B , participant require discontinuation previous ( peg ) interferon/ribavirin therapy adverse event consider investigator relate ( peg ) interferon and/or ribavirin For Study Part B , participant currently take antiviral/immunomodulatory treatment hepatitis C Participant take investigational drug , except boceprevir Participant receive follow medication ( ) within 2 week prior Day 1 visit : midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) Participation clinical trial within 30 day enrollment intent participate another clinical trial participation current study Evidence decompensated liver disease Child Pugh score &gt; 6 ( class B C ) History diabetes hypertension bear prior 32 week gestation clinically significant ocular examination finding Preexisting clinically significant psychiatric condition ( ) Clinical diagnosis substance abuse Any preexist medical condition could interfere participation completion study Evidence active suspect malignancy Females pregnant , nursing , intend become pregnant study period Allergy sensitivity investigational product excipients</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>